Neonatal sitomegalovirus hepatiti ve kolestazda antiviral tedavi
Loading...
Date
2005-12-21
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Uludağ Üniversitesi
Abstract
Neonatal hepatit, değişik nedenlerle 3 aydan küçük süt çocuklarının karaciğerinde benzer morfolojik değişikliklere yol açan hastalıkların grubudur. Sitomegalovirus enfeksiyonu da neonatal hepatit nedenlerinden biridir. Kolestatik süt çocuklarının yaklaşık % 40’ının etiyolojisinde neonatal hepatit vardır. Sitomegalovirus hepatosit ve kolanjiositleri enfekte ederek çoğalır. İmmün yetersizliği olmayan süt çocuğunda da latent; akut kolestatik veya kronik hepatite yol açabilir. Özellikle ağır olgularda Gansiklovir tedavi şansı değerlendirilmelidir. Ocak 2003-Ocak 2005 arasında CMV neonatal hepatit tanısı alan 12 olguda çalışma yapıldı. Grup 1, 7 bebekten oluşup 21 gün süreyle gansiklovir tedavisi uygulandı. Grup 2, 5 bebekten oluşup antiviral tedavi almadı. Her 2 gruptan çocukların başlangıç ve 3 ay sonra fizik muayene, biyokimya, serolojik değerleri karşılaştırılarak gansiklovir tedavisinin kolestetik hepatitte uygun ve güvenilir olduğu sonucuna varıldı.
Neonatal hepatitis refers to a heterogenous group of disorders that result in a some what similar morphologic change in the liver of an infant less than 3 months of age, in response to various insults, including cytomegalovirus infection. Neonatal hepatitis is responsible for approximately 40% of the cases of infants with cholestasis. Cytomegalovirus may infect and replicate in both hepatocytes and cholangiocytes. It may be cause latent or acut cholestatic or chronic hepatitis, including cirrhosis in immunocompatent infant too. It must be discussed treatment choice with ganciclovir particularly in severe cases. In our center, 12 cases with CMV neonatal hepatitis were diagnosed in betwen January 2003-January 2005. Group 1 was consisted of seven babies who were treated with ganciclovir during 21 days. Five cases who were not given antiviral treatment were described as group 2. Physical examination, biochemical tests, antiviral serology were done both groups at the time of diagnosis and repeated at the third month. This study revealed that ganciclovir treatment was safe and efficient in the cholestatic hepatitis cases.
Neonatal hepatitis refers to a heterogenous group of disorders that result in a some what similar morphologic change in the liver of an infant less than 3 months of age, in response to various insults, including cytomegalovirus infection. Neonatal hepatitis is responsible for approximately 40% of the cases of infants with cholestasis. Cytomegalovirus may infect and replicate in both hepatocytes and cholangiocytes. It may be cause latent or acut cholestatic or chronic hepatitis, including cirrhosis in immunocompatent infant too. It must be discussed treatment choice with ganciclovir particularly in severe cases. In our center, 12 cases with CMV neonatal hepatitis were diagnosed in betwen January 2003-January 2005. Group 1 was consisted of seven babies who were treated with ganciclovir during 21 days. Five cases who were not given antiviral treatment were described as group 2. Physical examination, biochemical tests, antiviral serology were done both groups at the time of diagnosis and repeated at the third month. This study revealed that ganciclovir treatment was safe and efficient in the cholestatic hepatitis cases.
Description
Keywords
CMV, Neonatal hepatit, Gansiklovir tedavisi, Kolestaz, Cholestasis, Neonatal hepatitis, Ganciclovir treatment
Citation
Özkan, T. B. (2005). ''Neonatal sitomegalovirus hepatiti ve kolestazda antiviral tedavi''. Uludağ Üniversitesi Tıp Fakültesi Dergisi, 31(2), 103-106.